Refractory SJIA and the Dangers of Subclinical MAS: A Survivor Story

Our Twitter Feed

Our Facebook Page

Timeline photosOn 28 February 2023, the rare disease community will come together to spread hope and solidarity in a ✨ Global Chain of Lights ✨You can #LightUpForRare by:🔦 Illuminating a monument in your city!🔦 Lighting up your home using our filters and in the Rare Disease Day colours!🔦 Posting your pictures with the hashtag #LightUpForRare on social media!👉 Learn how to illuminate a building: cutt.ly/jYNFp5X👉 Learn how to light up your home: cutt.ly/UYNFkKVTell us in the comments how you will #LightUpForRare!...#RareDiseaseDay #RareDiseases #ShareYourColours #LightUpForRare #Awareness #Support #Worldwide #Equity #Community ... See MoreSee Less
View on Facebook
Please join this free talk by an HLH expert if you are interested in SJIA and MAS. MAS shares a lot in common with HLH. Additionally many new MAS and SJIA treatments have been first used in HLH (e.g., ruxolitinib, emapalumab and bone marrow transplantation). Additionally Michael Jordan is one of the top experts on HLH and a great speaker. ... See MoreSee Less
View on Facebook

Keep in touch. Sign up for our email updates.